Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04902040
Title Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

urinary bladder cancer

Advanced Solid Tumor

Merkel cell carcinoma

renal cell carcinoma

lung small cell carcinoma

lung non-small cell carcinoma

melanoma

Therapies

Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin

Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.